For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesApril 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to [email protected]. AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to [email protected] with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to [email protected] with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.


Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213

Headlines

Bailey Named Director of UW Carbone
Howard H. Bailey, MD, has been named director of the University of Wisconsin Carbone Cancer Center. A professor of medicine at the UW School of Medicine and Public Health, Dr. Bailey is a medical oncologist who specializes in gynecologic and soft-tissue cancers and cancer prevention. He has served as interim director of the UW Carbone Cancer Center since September 2013. more...

Register Today: Hill Day Presents Opportunity to Request Enhanced
   and Sustained Support for NIH, NCI

AACI is co-hosting Hill Day on Thursday, May 7, with the American Association for Cancer Research and American Society of Clinical Oncology. The annual Hill Day reception will take place on Wednesday, May 6, from 6:00-7:30 pm on Capitol Hill. Participants will honor two Members of Congress who have displayed leadership on issues impacting the cancer community.

Please take time to register today. Feel free to contact Jennifer Pegher Government Relations Manager, at AACI at 412-647-0557 with questions. more...


AACI Earns CEO Roundtable Gold Standard Rating
The CEO Roundtable on Cancer has accredited the Association of American Cancer Institutes with the CEO Cancer Gold Standard™ recognizing the association's efforts to reduce the risk of cancer for its employees and covered family members. The Gold Standard employer status took effect March 1. more...

Online Registration Opens April 8 for 2015 AACI/CCAF Annual Meeting
The 2015 AACI/CCAF Annual Meeting will be held in Washington, DC, October 25-27. Information on the meeting, including the program and electronic registration, will be available on the AACI website on Wednesday, April 8. more...
News from the Centers
Awards & Honors
Davidson Selected as AACR President-Elect
American Association for Cancer Research (AACR)
The members of the American Association for Cancer Research (AACR) have elected Nancy E. Davidson, MD, director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter, as their president-elect for 2015-2016. She will officially become president-elect at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22, and will assume the presidency in April 2016. more...
Sawyers Honored with Frontiers of Knowledge Award
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD, Chair of Memorial Sloan Kettering Cancer Center's Human Oncology and Pathogenesis Program, has been named a recipient of the BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category for "opening the door to the personalized treatment of cancer." Dr. Sawyers shares the award with Tony Hunter, Director of the Salk Institute Cancer Center, and Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale University School of Medicine. more...
Low Honored for Outstanding Achievement in Chemistry in Cancer Research
American Association for Cancer Research (AACR)
The American Association for Cancer Research (AACR) will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. Dr. Low is the Ralph C. Corley distinguished professor of chemistry and director of the Center for Drug Discovery at Purdue University. more...
Moffitt Achieves Prestigious Nursing Magnet® Recognition
Moffitt Cancer Center
Moffitt Cancer Center has earned the prestigious Magnet® designation in recognition of its nursing excellence. Magnet® recognition is granted by the American Nurses Credentialing Center (ANCC), the credentialing body of the American Nurses Association, to honor outstanding health care organizations for nursing professionalism, teamwork, quality patient care and innovations in nursing practices. Today, only seven percent of national and international health care organizations are recognized by the ANCC Magnet Recognition Program®. more...
Massagué Wins Charles Rodolphe Brupbacher Prize
Memorial Sloan Kettering Cancer Center
Joan Massagué, PhD, Director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center, was honored with the 2015 Charles Rodolphe Brupbacher Prize for Cancer Research. Dr. Massagué, who shared the award with Irving L. Weissman, MD, of Stanford University, is being recognized for his research on the metastatic spread of cancer. He successfully demonstrated that genes are involved in the metastatic process that may not have been particularly significant in the development of the primary tumor. more...
Penne to Receive ONS Excellence in Surgical Oncology Award
Duke Cancer Institute
The Oncology Nursing Society has named Kara Penne, RN, MSN, ANP, AOCNP, to receive the 2015 ONS Excellence in Surgical Oncology Award. Penne, a surgical oncology team lead at the Duke Cancer Center, is being recognized for her expertise in the field of surgical oncology, having demonstrated a significant contribution to surgical oncology, patient education, clinical practice and nursing research. more...
Wood to Receive Early Career Award
Duke Cancer Institute
Kris Wood, PhD, assistant professor of Pharmacology and Cancer Biology, at Duke Cancer Institute, has been named to receive the 2015 Liz Tilberis Early Career Award from the Ovarian Cancer Research Fund. Launched in 2000 to honor OCRF's late president Liz Tilberis, the award is given to junior faculty demonstrating a strong commitment to an investigative career in ovarian cancer research. more...
Grants & Gifts
Baylor Receives Additional $11 Million in State Cancer Funding
The Dan L. Duncan Cancer Center
Researchers in the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received nine new grants totaling $11.3 million - a majority focused on advancing research into pediatric cancer - in the latest round of funding awarded by the Cancer Prevention and Research Institute of Texas. The newest grants bring Baylor's total CPRIT funding to more than $140 million since the agency began awarding cancer research funding in January 2010. more...
Leadership Transitions
Varmus Steps Down as NCI Director; Lowy Acting Director
National Cancer Institute
Harold Varmus, MD, has stepped down as director of the National Cancer Institute (NCI) after nearly five years. His last day on the job was March 31. Douglas Lowy, MD, has been named acting director for NCI beginning April 1. Dr. Lowy received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus vaccine. more...
Khuri Named President of American University of Beirut
Winship Cancer Institute
Fadlo R. Khuri, MD, deputy director of Winship Cancer Institute of Emory University, chair of the Department of Hematology and Medical Oncology, and executive associate dean for research at Emory University School of Medicine, was named president of American University of Beirut in Beirut, Lebanon. He will begin his tenure there on September 1 following a formal inaugural ceremony. more...
Gilbertson Resignation from St. Jude Announced
Comprehensive Cancer Center St. Jude Children's Research Hospital
St. Jude Children's Research Hospital has announced that the institution's scientific and Comprehensive Cancer Center director, Richard Gilbertson, MD, PhD, will return to his native England and become the director of the Cambridge Cancer Centre at the University of Cambridge. Dr. Gilbertson joined St. Jude in 2000. Under his leadership, the St. Jude Comprehensive Cancer Center achieved a score of "exceptional" in 2013, the highest rating awarded by the National Cancer Institute. more...
Waldinger to Retire as Chief Administrative Officer
University of Michigan Comprehensive Cancer Center
Marcy Waldinger, MHSA, has announced her retirement from the University of Michigan. Waldinger has been chief administrative officer of the university's Comprehensive Cancer Center since 1992, just one year after the center first received its comprehensive status. Waldinger will continue as a senior advisor to new Cancer Center director Theodore Lawrence, MD, PhD. Her retirement is effective April 3. more...
Winship Names New Chief Medical and Quality Officers
Winship Cancer Institute
Winship Cancer Institute of Emory University has named Sagar Lonial, MD, as chief medical officer and Charles A. Staley, MD, as chief quality officer, effective February 2015. Both physicians join Winship’s senior leadership team and will advance Winship’s clinical programs and services within all of its clinical facilities. more...
Mullins Joins UACC as Chief Administrative Officer
The University of Arizona Cancer Center
Meredith Mullins, JD, MBA, has joined the University of Arizona Cancer Center as associate director of administration. Mullins most recently was vice president for administration at the Levine Cancer Institute of the Carolinas HealthCare System, headquartered in Charlotte. She has extensive administration experience at cancer centers, including the Nevada Cancer Institute; the Barbara Ann Karmanos Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Oregon Health Sciences University Knight Cancer Institute, and the Medical University of South Carolina. more...
Colorado Hires Associate Director for Cancer Prevention and Control
University of Colorado Cancer Center
The University of Colorado Cancer Center and the Colorado School of Public Health have teamed to hire an associate director for cancer prevention and control. Cathy J. Bradley, PhD, comes to the University of Colorado's Anschutz Medical Campus from Virginia Commonwealth University where she is associate director at VCU's Massey Cancer Center. more...
Research Highlights
New Brain Cancer Clinical Trial Launched at CTRC
Cancer Therapy and Research Center at the University of Texas Health Science Center
David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor. The technology, developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, uses tiny radioactive liposomes, or fat particles, only 100 nanometers across, inserted by the thinnest of catheters directly into a tumor. There they remain, radiating only a tiny distance, affecting only the tumor. more...
Argos Application Gets Researchers, Clinicians Closer to Tailoring Precise Treatments
Fred Hutchinson Cancer Research Center
The Fred Hutchinson Cancer Research Center, in conjunction with LabKey Software, has developed and launched Argos, an application that provides the interface and analytical power that researchers and clinicians will use to search for important patterns in cancer development, progression and treatment response. Argos is built on the Hutch Integrated Data Repository and Archive, which merges the thousands of medical records, databases and tissue inventories maintained by the Fred Hutch/University of Washington Cancer Consortium. more...
Kidney Cancer Detected Early with Urine Test
Siteman Cancer Center
Researchers at Washington University School of Medicine in St. Louis have developed a noninvasive method to screen for kidney cancer that involves measuring the presence of proteins in the urine. Evan D. Kharasch, MD, PhD, is lead author on the study. more...
'Docking Stations' on Chromosomes New Anti-Cancer Target
Vanderbilt-Ingram Cancer Center
Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. The protein, WDR5, is a "docking station" for a family of transcription factors called MYC that is overexpressed in the majority of malignancies and which contributes to an estimated 100,000 cancer-related deaths each year in the United States. William Tansey, PhD, is lead author on the study. more...
UCSF to Study Benefits of Personal Approach to Breast Cancer Screening
UCSF Helen Diller Family Comprehensive Cancer Center
A research team at UC San Francisco has won a five-year award of $14.1 million from the Patient-Centered Outcomes Research Institute (PCORI) to investigate whether a personalized approach to breast cancer screening is as safe and effective as annual mammograms. The project, called the WISDOM study, will be led by breast cancer researcher Laura Esserman, MD, MBA, professor of surgery and director of the Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center. more...
Two Distinct Populations of CD4 T Cells Play Different Roles in Immune System
Dartmouth-Hitchcock Norris Cotton Cancer Center
Edward Usherwood, PhD and collaborators, through a novel transgenic mouse model, have discovered two populations of CD4 T cells. One population performs antiviral functions, and another survives life in the host. Recent research indicates that CD4 (helper T) cells play important roles in immune control of gammaherpesviruses, which can cause cancer. According to Usherwood, using the mouse model and flow cytometry from Dartlab allowed for a more detailed study of the CD4 T cell response. more...
Scientists Find How to Change Human Leukemia Cells into Harmless Immune Cells
Stanford Cancer Institute
Researchers at the Stanford University School of Medicine have discovered that when a certain aggressive leukemia is causing havoc in the body, the solution may be to force the cancer cells to grow up and behave. After a chance observation in the lab, the researchers found a method that can cause dangerous leukemia cells to mature into harmless immune cells known as macrophages. Ravi Majeti, MD, PhD, was senior author on the study. more...
Saccharin Shows Promise as Cancer Inhibitor, Researchers Find
UF Health Cancer Center
For decades, saccharin was wrongly labeled as a possible cancer-causing chemical. Now, nearly 15 years after it was declared safe, University of Florida Health researchers have found that the artificial sweetener can inhibit cancer cell growth. Saccharin shows considerable promise for its ability to inhibit an enzyme upregulated in many cancers, helping tumor cells survive and metastasize. After testing its effectiveness on cancer cells, researchers believe saccharin could eventually lead to the development of drugs that treat highly aggressive cancers affecting the breast, liver, prostate, kidney and pancreas. more...
Unregulated Web Marketing of Genetic Tests for Personalized Cancer Care Raises Concerns
Dana-Farber Cancer Institute
Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute. Stacy Gray, MD, AM, is first author of the report. more...
UNC Researcher Co-Leads Mapping Genomic Changes in Head and Neck Cancer
UNC Lineberger Comprehensive Cancer Center
A study co-led by UNC Lineberger Comprehensive Cancer Center researcher D. Neil Hayes, MD, MPH, has identified genomic changes in head and neck cancers linked to the sexually transmitted disease HPV -- the latest finding of a collaborative scientific effort designed to map out the genomic changes driving cancer. The study by The Cancer Genome Atlas researchers analyzed the genomes of 279 head and neck cancer tumors. They identified subtypes of head and neck cancer based on their genomic characteristics, changes in smoking-related tumors, as well as genomic differences in head and neck cancer tumors linked to HPV. more...
Study Reveals Effective Treatment for Breast Cancer Survivors with Post Treatment Memory Loss
Jonsson Comprehensive Cancer Center, UCLA
A new study led by UCLA Jonsson Comprehensive Cancer Center member Patricia Ganz, MD, could help improve the day-to-day quality-of-life for women with breast cancer. Dr. Ganz and her colleagues have developed a cognitive rehabilitation program to address post-cancer treatment cognitive changes, sometimes known as "chemo brain". more...
Researchers Use Scent-Trained Dogs to Detect Thyroid Cancer
UAMS Winthrop P. Rockefeller Cancer Institute
Researchers from the University of Arkansas for Medical Sciences presented findings at the Endocrine Society’s ENDO 2015 conference in San Diego showing nearly 90 percent accuracy using scent-trained dogs to detect thyroid cancer. The study took dogs already trained for scent detection and imprinted them with fresh tissue taken from patients diagnosed with papillary thyroid carcinoma. more...
Interaction of Estrogen Receptor and Coactivators Seen for First Time
The Dan L. Duncan Cancer Center
For more than 50 years, Bert O'Malley, MD, chair of Baylor College of Medicine's department of molecular and cellular biology, has worked to understand the estrogen receptor, how it works and how it partners with other molecules in the cell. In a recent study with Wah Chiu, PhD, Dr. O'Malley for the first time visualized the 900 kiloDalton molecular machine (kiloDalton is a measurement of mass) made up of the receptor, its coactivator SRC-3 (steroid receptor coactivator 3), another coactivator called p300, and the DNA that it controls, through the use of an electron cryo-microscope and advanced computational analysis. more...
Mapping of Ovarian Cancer Tumor Cell Microenvironment Highlights Role of T Cells
Roswell Park Cancer Institute
Understanding the chemokine landscape of papillary serous ovarian cancer, the most common form of the disease, is important for the development of new immunotherapy strategies where the goal is to increase the presence and function of T cells in the tumor microenvironment. New research examining the molecular environment of ovarian cancer is the first to map the presence of chemokines, immune-system proteins that mobilize T cells in this disease. more...
Clinical Trial Suggests Combination Therapy is Best for Low-Grade Brain Tumors
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada. Arnab Chakravarti, MD, is the trial's translational research national study chair. more...
Gene Mutations May Predict Melanoma Response to Immunotherapies
Vanderbilt-Ingram Cancer Center
Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center investigators. Douglas Johnson, MD, assistant professor of Medicine, and Christine Lovly, MD, PhD, assistant professor of Medicine and Cancer Biology, are co-first authors of the study, conducted in conjunction with colleagues from Memorial Sloan Kettering Cancer Center, New York, and Massachusetts General Hospital, Boston. more...
Skin Tumors Develop Specific Mutations to Resist Drug, Researchers Say
Stanford Cancer Institute
Among people with advanced basal cell carcinomas who see their skin cancers shrink or disappear in response to a common drug therapy, about 20 percent will relapse within months as the cancer cells become resistant to the treatment. Now, researchers at the Stanford University School of Medicine have identified specific mutations in the cancer cells that confer resistance to the drug, vismodegib, which is sold under the brand name Erivedge. They've also shown that another class of drug, called a Gli antagonist, may be able to successfully tackle even vismodegib-resistant cancers. more...
Genetic Markers May Point to Who Benefits from Aspirin, NSAIDs in Reducing Colorectal Cancer Risk
Melvin and Bren Simon Cancer Center, Indiana University
Hongmei Nan, MD, PhD, and collaborators from the Fred Hutchinson Cancer Research Center and the Massachusetts General Hospital have identified genetic markers that may help determine who benefits from regular use of aspirin and other nonsteroidal anti-inflammatory drugs for lowering one's risk of developing colorectal cancer. Previous studies have shown that regular use of aspirin and NSAIDs lower one's risk of colorectal cancer, but their use is not recommended as a way to prevent the disease because of uncertainty about the risks and benefits. more...
Research Leads to Trial for Relapsed/Refractory Aggressive Lymphomas
VCU Massey Cancer Center
Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, MD, is the co-principal investigator on a National Comprehensive Cancer Network grant funding a phase 1 clinical trial testing the drugs volasertib and belinostat in patients with relapsed and refractory aggressive B-cell and T-cell lymphomas. The $453,852 award will help implement the clinical trial at Massey, Yale Comprehensive Cancer Center and Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center. more...
Breast Cancer Prevention Drug Benefit Varies Among At-Risk Women, Study Finds
UNC Lineberger Comprehensive Cancer Center
After weighing the risk of serious side effects with the benefits of a breast cancer prevention drug, a study led by Hazel Nichols, PhD, found that the drug's benefits outweighed risks for most, but not all women. The study's findings may help women and their doctors make decisions about who may get the most benefit out of taking the drug tamoxifen, which has been shown to have been adopted by only a slim margin of women eligible to take it. more...
A One-Two Vaccine Punch Could Leave Brain Tumors Vulnerable to the Immune System
UF Health Cancer Center
A common booster vaccine could improve the effect of a vaccine aimed at treating a type of brain tumor, leading to improvement in patient survival, according to research published in the journal Nature. Vaccine therapies have been increasingly used to treat different types of cancer, including glioblastoma. In glioblastoma the team, which included researchers from Duke Cancer Institute and University of Florida Health, targeted cytomegalovirus, which is present in glioblastoma tumors, but not in surrounding brain tissue. more...
Why Some Colorectal Cancer Cells are "Born to be Bad"
USC Norris Comprehensive Cancer Center
Employing a "Big Bang" model of human colorectal cancer growth, USC Norris Comprehensive Cancer Center researchers have traced the origins of colorectal cancer cells and discovered important clues about their development. The team, led by Darryl Shibata, MD, and Christina Curtis, PhD, MsC, discovered that many cancer cells expressed abnormal mobility and intermixing that enabled them to metastasize in the body. Other cells that did not intermix became benign adenomas. more...
Young Adults Engaged in Other Risky Behaviors More Likely to Use E-Cigarettes
Roswell Park Cancer Institute
College students who use tobacco products, marijuana and/or binge drink also are more likely to use electronic cigarettes, or e-cigarettes, according to results of a survey conducted by researchers at Roswell Park Cancer Institute and the University at Buffalo. more...
Strategies Developed to Improve Colorectal Cancer Screening Rates in Low-Income and Minority Populations
University of Kansas Cancer Center
K. Allen Greiner, MD, MPH, member of The University of Kansas Cancer Center's Cancer Control and Population Health program, is working on developing strategies to improve screening rates in low-income and minority populations. Dr. Greiner and his team are using something called "implementation intentions" questions to determine what will help people get screened for colorectal cancer. The results were published in a recent issue of the American Journal of Preventive Medicine. more...
Favorable 15-Year Survival Outcomes Seen for Older Prostate Cancer Patients with Low-Risk Disease
Rutgers Cancer Institute of New Jersey
Results from a population-based study from investigators at Rutgers Cancer Institute of New Jersey show favorable survival outcomes among patients with low-risk prostate cancer treated with conservative management initially. Grace Lu-Yao, PhD, MPH, is lead author of the study. more...
Long-Needed Answers for Prostate Cancer Patients
University of Virginia Cancer Center
Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects. The findings inform a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant therapy - radiation given soon after prostate removal to kill off any remaining cancer cells - and many urologists preferring salvage therapy - radiation given later, when prostate-specific antigen tests suggest it's needed. more...
Innovative Light Therapy Reaches Deep Tumors
Siteman Cancer Center
Using a mouse model of cancer, researchers at Washington University School of Medicine in St. Louis and the Siteman Cancer Center have devised a way to apply light-based therapy to deep tissues never before accessible. Instead of shining an outside light, they delivered light directly to tumor cells, along with a photosensitive source of free radicals that can be activated by the light to destroy cancer. And they accomplished this using materials already approved for use in cancer patients. Samuel Achilefu, PhD, is senior author on the study. more...
Childhood Leukemia Study Reveals Disease Subtypes, New Treatment Option
UCSF Helen Diller Family Comprehensive Cancer Center
A new study of acute lymphoblastic leukemia (ALL), a blood cancer that primarily affects young children, has revealed that the disease has two distinct subtypes, and provides preliminary evidence that about 13 percent of ALL cases may be successfully treated with targeted drugs that have proved highly effective in the treatment of lymphomas in adults. Usually emerging in children between 2 and 5 years of age, ALL occurs when the proliferation of white blood cells known as lymphocytes spirals out of control. The current standard of care for ALL employs high doses of chemotherapy that usually cure the disease, but may also have serious long-term effects on brain development, bone growth and fertility, so there is an unmet need for better therapies. more...
Immunomagnetic Assay On-a-Chip Captures, Analyzes Circulating Tumor Cells
Dartmouth-Hitchcock Norris Cotton Cancer Center
Led by John X.J. Zhang, PhD, a team from the Thayer School of Engineering at Dartmouth has demonstrated a system that couples nano-engineered particles and microfluidic chips for capturing and manipulating circulating tumor cells. The system allows oncologists to isolate rare cells from whole blood to determine malignancy, helping to make prognoses and select therapies. Zhang hopes the technology will enable doctors to diagnose and manage cancer via simple blood tests. more...
Promising New Therapeutic Target for Prostate Cancer
USC Norris Comprehensive Cancer Center
USC Norris Comprehensive Cancer Center and Keck School of Medicine of USC researchers have discovered a member of a family of cell surface proteins that promotes prostate cancer growth and may present a new target for prostate cancer treatment. The protein, GPR158, is stimulated by androgens, which in turn stimulates androgen receptor expression and leads to tumor growth. more...
Other News
NCCN Publishes Guidelines for Smoking Cessation, Effort Led by OSU Oncologist
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

To meet the needs of patients who are smokers at the time of a cancer diagnosis, the National Comprehensive Cancer Network® (NCCN®) has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Smoking Cessation. The NCCN Guidelines Panel for Smoking Cessation, chaired by Peter G. Shields, MD, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), recommends that treatment plans for all smokers with cancer include the following: evidence-based pharmacotherapy, behavior therapy, and close follow-up with retreatment, as needed. more...
Job Opportunities
Executive Director, Research Administration (Cancer Center)   
The University of Miami, Miller School of Medicine

more...

Director, Research Operations 2015271  
Cancer Therapy & Research Center (CTRC)

more...

Director, Cancer Center Clinical Trials Office   
GRU Cancer Center

more...

Administrative Director, GRU Cancer Center Outpatient Facilities  
GRU Cancer Center

more...

Director  
University of Florida Health Cancer Center

more...

Meeting Announcements

2015 Capitol Hill Day - May 7

AACI will co-host its annual Capitol Hill Day with the American Association for Cancer Research (AACR), and American Society of Clinical Oncology (ASCO). Attendees will highlight how cancer research creates both health and economic benefits for the nation.

AACI is urging each cancer center to send at least one representative to Capitol Hill on May 7 to encourage Congress to enhance and sustain the support it currently lends to the NIH. Registration and accommodations can be found here.

7th Annual AACI Clinical Research Initiative Meeting

Save the Date!
July 8th, 8:00 am - July 9th, 5:00 pm CST
The Westin O'Hare
6100 North River Road, Rosemont, IL 60018

More information regarding accommodations and registration will be forthcoming.

2015 AACI/CCAF Annual Meeting

Save the Date!
October 25-27, 2015
Washington, DC